CHEK1 and small cell lung carcinoma: Similarly, a triple combined treatment of metronomic doses of gemcitabine with checkpoint kinase 1 (CHK1) inhibitor and anti-PD-L1/anti-PD-1, significantly increased antitumorigenic CD8+ cytotoxic T cells, DCs, and M1 macrophage populations in the SCLC model.